A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Clinical trial NCT02094573 · COMPLETED
Trial details
- NCT number
- NCT02094573
- Sponsor
- Ariad Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-04
- Primary completion
- 2016-02-29
- Enrollment
- 222
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.